Cell Line Optimisation - European Pharmaceutical Review

Login Here

Search

The Magazine

Product News

Industry News

Current Issue

Next Issue

Past Issues

Interviews

Show Previews

Testimonials

Company A-Z

Online Marketing Opportunities

Article Reprints

EPR Digital (Brand New!)

Subject Areas

Analytical Techniques

Aseptic Processing

Biomarkers

Biopharmaceutical

Cell Culture Automation

Cell Line Optimisation

Cellular Imaging

Chromatin

Cleanrooms

Clinical Development

Clinical Trials

Contract Sales

Drug Discovery

Drug Safety

Electrophysiology

European Pharmacopoeia

Freeze Drying

Functional Genomics

HCS

HTS

Ion Channel Drug Discovery

Ion Channel Electrophysiology

Ion Chromatography

Lab Automation

LIMS/ELNS

Lyophilization

Metabonomics

Microbiology

Microdialysis

Microdosing

Outsourcing

PAT

PCR

Personalised Medicine

Procurement

Project Management

Protein Crystallisation

Protein Crystallography

Proteomics

Raman Spectroscopy

Receptor Binding

RFID Technology

Rheology

Site Development

Stem Cells

Strategic Alliances

Tablet Compaction

Technology Transfer

Terahertz Spectroscopy

Thermal Analysis

Toxicology

Vaccine Technology

Events

Our Events

Industry Events

For Advertisers

Advert Specifications

Contact Sales

Industry Focus 2009

Media Pack

For Authors

Become a Contributor

Contact Editorial

Editorial Calendar

Notes for Authors

Russell Publishing Ltd
Court Lodge
Hogtrough Hill
Brasted
Kent TN16 1NU. UK
Registered in England
No. 2709148
Registered office as above.
VAT No. GB 577 897847

You are here: Home » Cell Line Optimisation

Cell Line Optimisation

Download

Print

Send a summary of this page to someone via email.

Recent articles

Maximising the efficiency and application of automated planar patch clamp electrophysiology Sep 21, 2007: The widespread expression of ion channels and their ability to significantly modulate cell function makes them attractive drug targets. Therapeutic agents which target ion channel proteins comprise the third best selling class of prescription drugs with US sales in 2002 estimated at $12 billion. Somewhat surprisingly the discovery of many marketed ion channel modulators was serendipitous rather than rational and these therapies target relatively few (less than 10) of the 400 ion channel genes contained within the human genome.